OBJECTIVE:Serum matrix metalloproteinases (MMP-8, MMP-7) and their regulators may be associated with the risk of incident cardiovascular disease events. Doxycycline can be used as matrix metalloproteinase (MMP) inhibitor independent of its antimicrobial activity. We aimed to investigate serum inflammatory biomarkers during 4 months of doxycycline therapy in coronary bypass patients. MATERIALS AND METHODS:Thirty-one non-smoking men who had previous coronary bypass surgery were randomly assigned to receive placebo or 100 mg doxycycline daily for 4 months. Serum samples were collected at baseline before the treatment, and at 2, 4, and 10 months. Serum levels of MMP-7, tissue inhibitor of matrix metalloproteinase (TIMP)-1, myeloperoxidase, andneutrophil elastase were analyzed with enzyme-linked immunosorbent assay, MMP-8 by immunofluorometric assay, and C-reactive protein by rate nephelometry. RESULTS: At baseline, no significant differences existed between the two groups. Serum levels of MMP-8, MMP-7, and MMP-8/TIMP-1 were and remained lower (p = 0.034, p = 0.041, and NS) in the doxycycline group relative to the placebo group at 4 months of follow-up. CONCLUSIONS:Doxycycline decreases the systemic inflammatory burden in patients with myocardial infarction and especially down-regulates MMP-7, MMP-8, and MMP-8/TIMP-1. Doxycycline might prevent or reduce the risk of secondary myocardial infarctions by providing a systemic anti-proteolytic and -inflammatory shield.
RCT Entities:
OBJECTIVE: Serum matrix metalloproteinases (MMP-8, MMP-7) and their regulators may be associated with the risk of incident cardiovascular disease events. Doxycycline can be used as matrix metalloproteinase (MMP) inhibitor independent of its antimicrobial activity. We aimed to investigate serum inflammatory biomarkers during 4 months of doxycycline therapy in coronary bypass patients. MATERIALS AND METHODS: Thirty-one non-smoking men who had previous coronary bypass surgery were randomly assigned to receive placebo or 100 mg doxycycline daily for 4 months. Serum samples were collected at baseline before the treatment, and at 2, 4, and 10 months. Serum levels of MMP-7, tissue inhibitor of matrix metalloproteinase (TIMP)-1, myeloperoxidase, and neutrophil elastase were analyzed with enzyme-linked immunosorbent assay, MMP-8 by immunofluorometric assay, and C-reactive protein by rate nephelometry. RESULTS: At baseline, no significant differences existed between the two groups. Serum levels of MMP-8, MMP-7, and MMP-8/TIMP-1 were and remained lower (p = 0.034, p = 0.041, and NS) in the doxycycline group relative to the placebo group at 4 months of follow-up. CONCLUSIONS:Doxycycline decreases the systemic inflammatory burden in patients with myocardial infarction and especially down-regulates MMP-7, MMP-8, and MMP-8/TIMP-1. Doxycycline might prevent or reduce the risk of secondary myocardial infarctions by providing a systemic anti-proteolytic and -inflammatory shield.
Authors: Marta Miguel Turu; Jerzy Krupinski; Esther Catena; Ana Rosell; Joan Montaner; Francisco Rubio; Jose Alvarez-Sabin; Marc Cairols; Lina Badimon Journal: Atherosclerosis Date: 2005-11-02 Impact factor: 5.162
Authors: Ricardo A García; Dennis P Pantazatos; Christopher R Gessner; Katrina V Go; Virgil L Woods; Francisco J Villarreal Journal: Mol Pharmacol Date: 2005-01-21 Impact factor: 4.436
Authors: Clare M Dollery; Caroline A Owen; Galina K Sukhova; Alexandra Krettek; Steven D Shapiro; Peter Libby Journal: Circulation Date: 2003-05-27 Impact factor: 29.690
Authors: Susanne W M van den Borne; Jack P M Cleutjens; Roeland Hanemaaijer; Esther E Creemers; Jos F M Smits; Mat J A P Daemen; W Matthijs Blankesteijn Journal: Cardiovasc Pathol Date: 2008-03-04 Impact factor: 2.185
Authors: Hilpi I Rautelin; Aino M Oksanen; Lea I Veijola; Pentti I Sipponen; Taina I Tervahartiala; Timo A Sorsa; Anneli Lauhio Journal: Ann Med Date: 2009 Impact factor: 4.709